BioSight
Companies
Greenwich LifeSciences, Inc. logo

GLSI

NASDAQSTAFFORD, TX
Greenwich LifeSciences, Inc.

Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing GLSI-100, a cancer immunotherapy combining the HER2/neu peptide GP2 with GM-CSF, currently in Phase III evaluation through the Flamingo-01 trial for breast cancer recurrence prevention in HER2/neu-positive patients with residual disease or high-risk pathologic complete response following trastuzumab-based treatment. The company is expanding Flamingo-01 globally with plans to open up to 150 sites across Europe and other regions to evaluate the safety and efficacy of this immunotherapy approach in oncology.

Price history not yet available for GLSI.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar